Nicotine Polacrilex

Category
Smoking Cessation
Product code
96055-45-7

Nicotine Polacrilex is a nicotine-replacement active pharmaceutical ingredient widely used to support smoking cessation. By delivering controlled amounts of nicotine through buccal absorption, Nicotine Polacrilex helps reduce withdrawal symptoms and cravings, facilitating gradual cessation of tobacco use. Its polymer-bound formulation allows for sustained release and improved adherence compared to conventional nicotine products. Pharmaceutical companies formulate Nicotine Polacrilex into chewing gums and lozenges, providing convenient and flexible dosing options for adult smokers seeking to quit.

Common Nicotine Polacrilex Uses and Treated Conditions

  • Smoking Cessation – Reduces nicotine cravings and withdrawal symptoms during quit attempts.
  • Tobacco Dependence Management – Supports behavioral therapy and gradual nicotine tapering.
  • Relapse Prevention – Helps maintain abstinence in individuals recovering from nicotine addiction.
  • Short-Term Nicotine Replacement – Provides controlled nicotine delivery to reduce acute withdrawal episodes.

Why Choose Cambrex as Your Generic API Manufacturer?

As a leading generic API supplier, Cambrex manufactures Nicotine Polacrilex API in cGMP-compliant facilities, ensuring every batch meets stringent global quality and regulatory standards. Our technical expertise, robust quality systems, and proven regulatory track record empower clients to accelerate development timelines and achieve successful market approvals. We prioritize transparency, reliability, and scientific rigor at every stage of the supply chain making us your trusted generic API manufacturer.

For detailed chemical information on Nicotine Polacrilex, visit the official CAS website.

If you’d like more information or to request a sample, contact our Generic API team today.

Nicotine Polacrilex

Cambrex your API partner

Cambrex are a leading global supplier of generic APIs. From our sites in Italy, Sweden, and the USA, we work with generic drug companies well in advance of drug patent expiration, using high quality, non-patent-infringing processes to manufacture APIs.

Contact us